Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Key Highlights
- ➤Labcorp (LH) and Waters (WAT) plan U.S. HPV testing partnership beginning late 2026
- ➤Labcorp will offer testing across clinics, patient centers, and at-home settings
- ➤Labcorp’s network spans over 850,000 providers and more than 2,200 patient centers
- ➤BD Onclarity is the only FDA-approved HPV test supporting all ASCCP enduring guidelines
- ➤BD Onclarity individually identifies six high-risk HPV genotypes and strategically pools three groups
Expert Statements
Jeff Andrews, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation
“Barriers such as privacy, access, and socioeconomic factors can make it difficult to stay current with cervical cancer screening.”
Jeff Andrews, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation
“We are at the start of a new era in which screening can extend beyond the clinic, enable more personalized risk assessment, and reach people who have historically been underserved.”
Jeff Andrews, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation
“By offering greater flexibility in how and where people are screened, our collaboration marks a critical step forward in bridging one of today’s most profound care gaps.”
Brian Caveney, Chief Medical and Scientific Officer, Labcorp
“Cervical cancer screening saves lives, but too many women still face barriers to getting screened.”
Brian Caveney, Chief Medical and Scientific Officer, Labcorp
“By expanding access and options for comprehensive FDA-approved HPV testing, we can help more women stay current with recommended screening, reach those who may be overdue for care, and support earlier identification of cervical cancer risk.”
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 PR Newswire
* Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings * Through a network serving more than 850,000 physicians and healthcare providers and more than 2,200 patient service centers, Labcorp is helping expand access to cervical cancer screening nationwide * First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping MILFORD, Mass. and BURLINGTON, N.C., Oct. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026.
Get started
Create a free account to read the full story.